Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1600132/000110465915024173/a15-8010_110k.htm
SEC Filings
BLPH Annual Reports
BLPH Quarterly Reports
10-Q Quarterly Report May 2023
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report May 2023
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
BLPH Corporate News
Financial Exhibit
Other Events June 2023
Earnings Release
Financial Exhibit May 2023
Event for Officers May 2023
Financial Exhibit
Other Events May 2023
Event for Officers
Financial Exhibit May 2023
Event for Officers April 2023
Earnings Release
Financial Exhibit March 2023
Financial Exhibit
New Agreement March 2023
Other Events March 2023
Financial Exhibit
Other Events February 2023
Financial Exhibit
Other Events
Other Events
June 2023
Earnings Release
Financial Exhibit
Financial Exhibit
May 2023
Event for Officers
May 2023
Financial Exhibit
Other Events
Other Events
May 2023
Event for Officers
Financial Exhibit
Financial Exhibit
May 2023
Event for Officers
April 2023
Earnings Release
Financial Exhibit
Financial Exhibit
March 2023
Financial Exhibit
New Agreement
New Agreement
March 2023
Other Events
March 2023
Financial Exhibit
Other Events
Other Events
February 2023
Last10K.com | 10-K Annual Report Tue Mar 31 2015
View differences made from one year to another to evaluate Bellerophon Therapeutics, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Bellerophon Therapeutics, Inc..
Assess how Bellerophon Therapeutics, Inc.'s management team is paid from their Annual Proxy
Bellerophon Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Material Contracts, Statements, Certifications & more
Bellerophon Therapeutics, Inc. provided additional information to their SEC Filing as exhibits
Exhibit 2.1: Plan Of Acquisition, Reorganization, Arrangement, Liquidation Or Succession
Exhibit 2.2: Plan Of Acquisition, Reorganization, Arrangement, Liquidation Or Succession
Exhibit 4.2: Instruments Defining The Rights Of Security Holders, Including Indentures
Exhibit 4.3: Instruments Defining The Rights Of Security Holders, Including Indentures
Exhibit 10.8: Material Contract
Exhibit 10.16: Material Contract
Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Exhibit 32.2: Section 1350 Certification
Ticker: BLPH
CIK: 1600132
Form Type: 10-K Annual Report
Accession Number: 0001104659-15-024173
Submitted to the SEC: Tue Mar 31 2015 6:04:31 AM EST
Accepted by the SEC: Tue Mar 31 2015
Period: Wednesday, December 31, 2014
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/blph/0001104659-15-024173.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...